/
/
Isatuximab with Carfilzomib and Dex Almost Doubles Remission Times In Recent Myeloma Study
Isatuximab with Carfilzomib and Dex Almost Doubles Remission Times In Recent Myeloma Study image
Isatuximab with Carfilzomib and Dex Almost Doubles Remission Times In Recent Myeloma Study
Posted May 25, 2022

Sarclisa (isatuximab) when used with carfilzomib and dexamethasone almost doubled progression free survival compared to patients who had carfilzomib and dexamethasone alone, according to new data from the IKEMA study. 

Presented at the Controversies in Multiple Myeloma World Congress in Paris, France, the combination reflects the longest median progression free survival of any proteasome inhibitor backbone therapy used for first-relapsed myeloma patients. 

Myeloma specialist Philippe Moreau, MD of the University Hospital of Nantes, France said: 

“The increase in progression free survival, observed consistently across all subgroups, when adding Sarclisa to carfilzomib and dexamethasone is remarkable in patients with relapsed multiple myeloma in a proteasome inhibitor combination. Relapse is common in multiple myeloma, creating the need for differentiated second-line treatments that provide patients a longer period of time without disease progression. This updated analysis reinforces the potential for Sarclisa to become a new standard of care for patients with relapsed multiple myeloma.”

The IKEMA study enrolled 302 relapsed myeloma patients from 69 centers in 16 countries. Myeloma patients in the study had received 1-3 prior myeloma therapies and included patients who had relapsed after lenalidomide. 

  IsaKd Kd
Median Progression Free Survival (IKEMA results) 35.7 months 19.2 months
Time to Next Treatment 44.9 months 25 months

 

The safety profile when used with carfilzomib and dex was consistent with what was seen in prior isatuximab trials with the most common side effects being as follows: 

  IsaKd Kd
infusion related reaction 45.8% 3.3%
diarrhea 39.5% 32%
high blood pressure 37.9% 35.2%
upper respiratory tract infection 37.3% 27%
fatigue 31.6% 20.5%
difficulty breathing 30.5% 22.1%
pneumonia 27.1% 21.3%
back pain 25.4% 21.3%
insomnia 24.3% 12.3%
bronchitis 25.4% 21.3%

 

Having a treatment combination for relapsed patients combined with a proteasome inhibitor (without an immunomodulator) that keeps patients in remission for more than three years is an impressive outcome for patients. We look forward to seeing additional data from additional isatuximab studies. 

 

 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811